A double-blind randomized controlled trial comparing 0.75mg of Palonosetron with 1mg of Granisetron for the control of highly emetogenic chemotherapy-induced emesis.

Trial Profile

A double-blind randomized controlled trial comparing 0.75mg of Palonosetron with 1mg of Granisetron for the control of highly emetogenic chemotherapy-induced emesis.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Palonosetron (Primary) ; Aprepitant; Dexamethasone; Granisetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms TRIPLE
  • Most Recent Events

    • 12 Sep 2017 Results (n=825) assessing risk factors of chemotherapy induced nausea and vomiting presented at the 42nd European Society for Medical Oncology Congress
    • 29 Jun 2016 Primary endpoint, (Complete control of nausea and vomiting) has not been met, according to a results published in the Annals of Oncology.
    • 29 Jun 2016 Results published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top